Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 247 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Latest episode of our podcast for cancer researchers March 23, 2022 Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... September 3, 2025 Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... July 6, 2022 Load more HOT NEWS Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... A Congress Bag for Women’s Empowerment New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... How to Support a Spouse or Partner During Cancer Treatment by...
